BELOHLAVEK, Jan, Jana SMALCOVA, Daniel ROB, Ondrej FRANEK, Ondrej SMID, Milana POKORNA, Jan HORAK, Vratislav MRAZEK, Tomas KOVARNIK, David ZEMANEK, Ales KRAL, Stepan HAVRANEK, Petra KAVALKOVA, Lucie KOMPELENTOVA, Helena TOMKOVA, Alan MEJSTRIK, Jaroslav VALASEK, David PERAN, Jaroslav PEKARA, Jan RULISEK, Martin BALIK, Michal HUPTYCH, Jiří JARKOVSKÝ, Jan MALIK, Anna VALERIANOVA, Frantisek MLEJNSKY, Petr KOLOUCH, Petra HAVRANKOVA, Dan ROMPORTL, Arnost KOMAREK and Ales LINHART. Effect of Intra-arrest Transport, Extracorporeal Cardiopulmonary Resuscitation, and Immediate Invasive Assessment and Treatment on Functional Neurologic Outcome in Refractory Out-of-Hospital Cardiac Arrest A Randomized Clinical Trial. JAMA-Journal of the American Medical Association. Chicago, USA: American Medical Association, 2022, vol. 327, No 8, p. 737-747. ISSN 0098-7484. Available from: https://dx.doi.org/10.1001/jama.2022.1025.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Effect of Intra-arrest Transport, Extracorporeal Cardiopulmonary Resuscitation, and Immediate Invasive Assessment and Treatment on Functional Neurologic Outcome in Refractory Out-of-Hospital Cardiac Arrest A Randomized Clinical Trial
Authors BELOHLAVEK, Jan (203 Czech Republic, guarantor), Jana SMALCOVA (203 Czech Republic), Daniel ROB (203 Czech Republic), Ondrej FRANEK (203 Czech Republic), Ondrej SMID (203 Czech Republic), Milana POKORNA (203 Czech Republic), Jan HORAK (203 Czech Republic), Vratislav MRAZEK (203 Czech Republic), Tomas KOVARNIK (203 Czech Republic), David ZEMANEK (203 Czech Republic), Ales KRAL (203 Czech Republic), Stepan HAVRANEK (203 Czech Republic), Petra KAVALKOVA (203 Czech Republic), Lucie KOMPELENTOVA (203 Czech Republic), Helena TOMKOVA (203 Czech Republic), Alan MEJSTRIK (203 Czech Republic), Jaroslav VALASEK (203 Czech Republic), David PERAN (203 Czech Republic), Jaroslav PEKARA (203 Czech Republic), Jan RULISEK (203 Czech Republic), Martin BALIK (203 Czech Republic), Michal HUPTYCH (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Jan MALIK (203 Czech Republic), Anna VALERIANOVA (203 Czech Republic), Frantisek MLEJNSKY (203 Czech Republic), Petr KOLOUCH (203 Czech Republic), Petra HAVRANKOVA (203 Czech Republic), Dan ROMPORTL (203 Czech Republic), Arnost KOMAREK (203 Czech Republic) and Ales LINHART (203 Czech Republic).
Edition JAMA-Journal of the American Medical Association, Chicago, USA, American Medical Association, 2022, 0098-7484.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30218 General and internal medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 120.700
RIV identification code RIV/00216224:14110/22:00126152
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1001/jama.2022.1025
UT WoS 000762147200020
Keywords in English Intra-arrest Transport; Extracorporeal Cardiopulmonary Resuscitation; Immediate Invasive Assessment and Treatment; Functional Neurologic Outcome
Tags 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 28/6/2022 10:54.
Abstract
IMPORTANCE Out-of-hospital cardiac arrest (OHCA) has poor outcome. Whether intra-arrest transport, extracorporeal cardiopulmonary resuscitation (ECPR), and immediate invasive assessment and treatment (invasive strategy) is beneficial in this setting remains uncertain. OBJECTIVE To determine whether an early invasive approach in adults with refractory OHCA improves neurologically favorable survival. DESIGN, SETTING, AND PARTICIPANTS Single-center, randomized clinical trial in Prague, Czech Republic, of adults with a witnessed OHCA of presumed cardiac origin without return of spontaneous circulation. A total of 256 participants, of a planned sample size of 285, were enrolled between March 2013 and October 2020. Patients were observed until death or day 180 (last patient follow-up ended on March 30, 2021). INTERVENTIONS In the invasive strategy group (n = 124), mechanical compression was initiated, followed by intra-arrest transport to a cardiac center for ECPR and immediate invasive assessment and treatment. Regular advanced cardiac life support was continued on-site in the standard strategy group (n = 132). MAIN OUTCOMES AND MEASURES The primary outcome was survival with a good neurologic outcome (defined as Cerebral Performance Category [CPC] 1-2) at 180 days after randomization. Secondary outcomes included neurologic recovery at 30 days (defined as CPC 1-2 at any time within the first 30 days) and cardiac recovery at 30 days (defined as no need for pharmacological or mechanical cardiac support for at least 24 hours). RESULTS The trial was stopped at the recommendation of the data and safety monitoring board when prespecified criteria for futility were met. Among 256 patients (median age, 58 years; 44 [17%] women), 256 (100%) completed the trial. In the main analysis, 39 patients (31.5%) in the invasive strategy group and 29 (22.0%) in the standard strategy group survived to 180 days with good neurologic outcome (odds ratio [OR], 1.63 [95% CI, 0.93 to 2.85]; difference, 9.5% [95% CI, -1.3% to 20.1%]; P = .09). At 30 days, neurologic recovery had occurred in 38 patients (30.6%) in the invasive strategy group and in 24 (18.2%) in the standard strategy group (OR, 1.99 [95% CI, 1.11 to 3.57]; difference, 12.4% [95% CI, 1.9% to 22.7%]; P = .02), and cardiac recovery had occurred in 54 (43.5%) and 45 (34.1%) patients, respectively (OR, 1.49 [95% CI, 0.91 to 2.47]; difference, 9.4% [95% CI, -2.5% to 21%]; P = .12). Bleeding occurred more frequently in the invasive strategy vs standard strategy group (31% vs 15%, respectively). CONCLUSIONS AND RELEVANCE Among patients with refractory out-of-hospital cardiac arrest, the bundle of early intra-arrest transport, ECPR, and invasive assessment and treatment did not significantly improve survival with neurologically favorable outcome at 180 days compared with standard resuscitation. However, the trial was possibly underpowered to detect a clinically relevant difference.
PrintDisplayed: 26/5/2024 11:00